Influence of Exceptional Patient Characteristics on Everolimus Exposure

Trial Profile

Influence of Exceptional Patient Characteristics on Everolimus Exposure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Acronyms INPRES
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
    • 19 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 01 Nov 2016 Results assessing the impact of hematocrit on pharmacokinetics and pharmacodynamics of everolimus in cancer patients (n=73) from THYRRAD and INPRES trials using semi-physiological pharmacokinetic model, published in the Clinical Pharmacokinetics Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top